In recent years, cell therapy technology has attracted much attention worldwide, and more and more research institutes and pharmaceutical companies have devoted themselves to research and development in this field. However, the key technical bottlenecks in cell therapy research have been restricting the rapid development of this field. In this regard, InnoModels Biotechnology has independently developed an innovative technology, iHuPBMC-T, which provides a brand new solution for cell therapy research.
iHuPBMC-T is a kind of mouse T cell with human T cell receptor (TCR) by fusing human peripheral blood mononuclear cell (PBMC) with mouse T cell using genetic engineering technology. This cell has both the human TCR, which recognizes and attacks specific human tumor cells, and the mouse immune system, which enables in vivo testing in mice.
The iHuPBMC-T technology introduced by InnoModels Biotechnology has the following advantages:
1. High recognition ability: iHuPBMC-T cells possess human TCR, which can highly recognize and attack specific human tumor cells.
2. High safety: iHuPBMC-T cells are derived from human peripheral blood single nucleus cells, which reduces the risk of immune rejection and tumor metastasis.
3. Wide range of application: iHuPBMC-T cells can be used in clinical trials for a variety of tumors, including solid tumors and hematological tumors, etc., which has a wider application potential.
4. Easy to operate: The preparation and application process of iHuPBMC-T cells is relatively simple, which helps the rapid advancement of research and clinical trials.
5. Avoidance of immune rejection: Due to the use of human PBMC, iHuPBMC-T cells can theoretically reduce immune rejection and improve the feasibility of treatment.
6. Tumor specificity: iHuPBMC-T cells can target specific tumor antigens, improving the precision of treatment.
7. Promoting immune memory: iHuPBMC-T cell treatment may activate immune memory, thus creating a long-term anti-tumor immune environment in the body.
8. Customizability: Depending on different tumor types and patient conditions, iHuPBMC-T cells can be customized and prepared to fit specific therapeutic needs.

With iHuPBMC-T technology, InnoModels Biotechnology brings innovative solutions to the field of cell therapy, which is expected to provide safer, more effective and more personalized treatment options for tumor patients.
InnoModels Biotechnology is committed to applying iHuPBMC-T technology in clinical practice, bringing new therapeutic hope to tumor patients around the world. The company has cooperated with many well-known pharmaceutical companies and research institutes at home and abroad to jointly promote the research and development of cell therapy technology.
In the future development, InnoModels Biotechnology will continue to increase its R&D efforts to optimize iHuPBMC-T technology and provide more innovative solutions for the cell therapy field. At the same time, the company will also join hands with its partners to jointly promote China's cell therapy business to a higher level and help the development of human health.
In conclusion, iHuPBMC-T technology independently developed by InnoModels Biotechnology provides a brand-new solution for cell therapy research, which is expected to bring a brand-new therapeutic hope to global tumor patients. In the wave of cell therapy field, InnoModels Biotechnology will continue to play a role in promoting the development of this field to new heights.